BioPharma Clinical Trials

Hong Kong's Akeso Biopharma Advances Immunotherapy in Biliary Tract Cancer with First Patient Enrolled in Phase III Study of Ivonescimab

 Akeso Biopharma (9926.HK) is pleased to announce the successful enrollment of the first patient in the HARMONi-GI-01/AK112-309 study, a randomized, c...

 November 01, 2024 | News

Hong Kong’s Akeso Biopharma Enrolls First Patient in Pioneering Phase III Trial for Advanced Head and Neck Cancer Therapy

Akeso Biopharma (9926.HK) is pleased to announce the enrollment of the first patient in its randomized, controlled, multicenter Phase III clinical study (A...

 October 31, 2024 | News

Clover Biopharmaceuticals' Non-Adjuvanted RSV Vaccine Candidate SCB-1019 Shows Promising Efficacy and Safety in Head-to-Head Comparison with GSK's AREXVY

- Head-to-head clinical results indicate a potential best-in-class combined efficacy & safety profile of non-adjuvanted bivalent RSV vaccine candi...

 October 29, 2024 | News

RiboX Therapeutics Secures FDA IND Clearance for First Circular RNA Therapy, Initiating Clinical Trials for RXRG001

RiboX Therapeutics Ltd. (RiboX), a pioneering biopharmaceutical company, focused on discovering and developing fully engineered circular RNA therapeutics, ...

 October 28, 2024 | News

LakeShore Biopharma Gains NMPA Approval for Phase III Trial of Simplified Four-Dose Rabies Vaccine Regimen

LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developin...

 October 28, 2024 | News

MicuRx Achieves Milestone with Successful Phase I Trial of Novel Antibacterial MRX-5 in Australia

Shanghai MicuRx Pharmaceutical Co., Ltd. ("MicuRx", 688373.SH) announced the successful completion of Phase I clinical trial of MRX-5 in Australi...

 October 28, 2024 | News

Corvia Medical’s Atrial Shunt Demonstrates Long-Term Efficacy in Heart Failure Patients: Three-Year Trial Results Published

Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure, announced impressive three-year results from its REDUCE LAP-HF II ...

 October 28, 2024 | News

South Korea’s Qurient Launches Phase 1 Clinical Trial for Adrixetinib in AML Following FDA IND Clearance

Qurient has announced the commencement of a clinical trial for adrixetinib (formerly named Q702), following the clearance of its investigational new drug (...

 October 25, 2024 | News

Pierre Fabre Doses First Patient with PFL-002/VERT-002, a Novel c-MET Degrader for MET-Altered Cancers

PFL-002/VERT-002 is a monoclonal antibody with a novel and differentiated mechanism of action, acting as a degrader of c-MET, with the potential to be...

 October 25, 2024 | News

Taiwan’s Caliway Biopharmaceuticals Completes Final Phase 2b Study of CBL-514, First Injectable for Large-Area Fat Reduction

The first and only lipolytic injectable for large area – CBL-514's last Phase 2b study has been completed Both CBL-514 Phase 2b&nbs...

 October 24, 2024 | News

Hope Medicine’s HMI-115 Shows Significant Pain Reduction in Endometriosis Phase 2 Trial

HMI-115 has demonstrated statistically significant improvement in endometriosis pain The mean dysmenorrhea pain score was reduced by 42% The mean non-m...

 October 24, 2024 | News

RAPT Therapeutics Boosts Drug Development Efficiency with INTEGRA Biosciences’ Pipettes for Cancer and Inflammatory Disease Research

RAPT Therapeutics in San Francisco, USA, relies on INTEGRA Biosciences’ pipettes to seamlessly accelerate the development of its candidate small...

 October 23, 2024 | News

SGS Launches Pioneering CDISC Open Rules Consultancy to Accelerate Clinical Trial Submissions

SGS, the world’s leading testing, inspection and certification company, has today launched its pioneering ‘CDISC Open Rules Consultancy’,...

 October 23, 2024 | News

Recursion Doses First Patient in Phase 2 Trial of REC-3964, a Novel Non-Antibiotic Treatment for Recurrent C. difficile Infection

REC-3964 is Recursion’s first new chemical entity developed using the RecursionOS. REC-3964 represents a novel, non-antibiotic approach with a uni...

 October 23, 2024 | News


Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close